Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials and real-world evidence

被引:0
作者
Kunutsor, Setor K. [1 ]
Seidu, Borenyi S. [1 ,2 ]
Seidu, Samuel [1 ]
机构
[1] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester Real World Evidence Unit, Gwendolen Rd, Leicester LE5 4WP, England
[2] Univ Manchester, Manchester, England
关键词
SGLT-2i; GLP-1RA; Type; 2; diabetes; Statins; Cardiovascular disease; Randomised controlled trial; MULTIFACTORIAL INTERVENTION; EMPAGLIFLOZIN; MORTALITY; KIDNEY; DISEASE; RISK; LIRAGLUTIDE; SIMVASTATIN; MECHANISM; MELLITUS;
D O I
10.1016/j.pcd.2024.09.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether the cardiovascular treatment benefits of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) differ by baseline use of statins/lipid lowering therapy is unclear. This systematic review and meta-analysis investigated whether baseline statin use (users vs non-users) influences the cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs in patients with type 2 diabetes (T2D). Methods: We identified relevant cardiovascular outcome trials (CVOTs) and observational cohort studies from MEDLINE, Embase, the Cochrane Library, and bibliographic searches up to March 2024. The analysis pooled study-specific hazard ratios (HRs) with 95 % confidence intervals (CIs) for outcomes, categorized by baseline statin use status. We also assessed the interactions between these medications and baseline statin use by calculating and pooling the ratio of HRs (RHRs) within each trial. Results: Twenty-five articles (13 articles comprising 6 unique CVOTs and 12 articles comprising 9 unique cohort studies) were eligible. In CVOTs of SGLT-2is, the HRs (95 % CIs) of MACE; composite of CVD death or hospitalisation for heart failure; stroke; and kidney events in statin users were 0.90 (0.82-1.00), 0.78 (0.60-1.02), 1.00 (0.77-1.31), and 0.60 (0.53-0.69), respectively. The corresponding estimates were similar in non-statin users. In CVOTs of GLP-1RAs, the HRs (95 % CIs) for MACE in statin and non-statin users were 0.81 (0.73-0.90) and 0.92 (0.77-1.11), respectively. In observational cohort studies, SGLT-2is similarly reduced the risk of several cardiovascular and kidney outcomes in both statin and non-statin users. The estimated RHRs and p-values for interaction indicated that baseline statin use status did not significantly modify the cardio-kidney benefits of SGLT-2is and GLP-1RAs. Conclusions: Aggregate analyses of intervention and real-world evidence show that SGLT-2is and GLP-1RAs provide comparable cardio-kidney benefits in patients with T2D, regardless of baseline statin use status. PROSPERO Registration: CRD42024498939
引用
收藏
页码:589 / 598
页数:10
相关论文
共 50 条
  • [31] Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis
    Gray, L. J.
    Dales, J.
    Brady, E. M.
    Khunti, K.
    Hanif, W.
    Davies, M. J.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (07) : 639 - 648
  • [32] Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials
    Zaccardi, Francesco
    Dhalwani, Nafeesa N.
    Dales, Jolyon
    Mani, Hamid
    Khunti, Kamlesh
    Davies, Melanie J.
    Webb, David R.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (04) : 985 - 997
  • [33] Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review
    Chan, Siew Pheng
    Lim, Lee-Ling
    Chan, Juliana C. N.
    Matthews, David R. R.
    [J]. DIABETES THERAPY, 2023, 14 (05) : 823 - 838
  • [34] Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis
    Liang, Tingting
    Xie, Xinqiang
    Wu, Lei
    Li, Longyan
    Yang, Lingshuang
    Gao, He
    Deng, Zhenshan
    Zhang, Xiangqian
    Chen, Xuefeng
    Zhang, Jumei
    Ding, Yu
    Wu, Qingping
    [J]. FRONTIERS IN NUTRITION, 2022, 9
  • [35] Meta-Analysis on the Efficacy of Novel Glucose-Lowering Agents in Older Patients With Type 2 Diabetes Mellitus
    Ahmed, Aymen
    Imran, Laiba
    Naeem, Unaiza
    Jawed, Areesha
    Jawed, Aleeza
    Khan, Zayeema
    Arshad, Abdul Rehman
    Arshad, Muhammad Sameer
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2023, 187 : 127 - 130
  • [36] Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials
    Anyanwagu, U.
    Mamza, J.
    Donnelly, R.
    Idris, I.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 69 - 85
  • [37] Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    Ponce, Oscar J.
    Larrea-Mantilla, Laura
    Hemmingsen, Bianca
    Serrano, Valentina
    Rodriguez-Gutierrez, Rene
    Spencer-Bonilla, Gabriela
    Alvarez-Villalobos, Neri
    Benkhadra, Khaled
    Haddad, Abdullah
    Gionfriddo, Michael R.
    Prokop, Larry J.
    Brito, Juan P.
    Murad, Mohammad Hassan
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (05) : 1585 - 1594
  • [38] Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis
    Diallo, Alhassane
    Carlos-Bolumbu, Miguel
    Galtier, Florence
    [J]. ECLINICALMEDICINE, 2022, 54
  • [39] Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease
    Zhang, Fang
    Ji, Linong
    Hong, Tianpei
    Guo, Lixin
    Li, Yan
    Zhu, Zhiming
    Liu, Xingbin
    Liu, Fang
    Tang, Lizhi
    Zhang, Yuwei
    Li, Juan
    Lu, Qingguo
    Tong, Nanwei
    [J]. JOURNAL OF EVIDENCE BASED MEDICINE, 2022, 15 (02) : 168 - 179
  • [40] Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis
    Wu, Sijia
    He, Yina
    Wu, Yutong
    Ji, Yiman
    Hou, Lei
    Liu, Xinhui
    Ge, Yilei
    Yu, Yuanyuan
    Yu, Yifan
    Wei, Yun
    Qian, Fengtong
    Luo, Qingxin
    Feng, Yue
    Feng, Yiping
    Wang, Jiongjiong
    Huo, Meiling
    Li, Hongkai
    Xue, Fuzhong
    Liu, Yunxia
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13